* Therapeutic Indications: Essential hypertension, where monotherapy with candesartan cilexetil or hydrochlorothiazide is not sufficient. | |
* Posology && Method of Administration: | |
# Dosage: | |
– The recommended dose of Atacand Plus is 1 tablet once daily. | |
– The dose of candesartan cilexetil should be titrated before switching to Atacand Plus. When clinically appropriate a direct | |
& change from monotherapy to Atacand Plus may be considered. Most of the antihypertensive effect is usually attained within | |
& 4 weeks of initiation of treatment. | |
# Administration: Atacand Plus should be taken once daily with or without food. | |
# Use in the elderly: Dose titration of candesartan cilexetil is recommended in elderly patients before treatment with Atacand Plus. | |
# Use in impaired renal function | |
& Loop diuretics are preferred to thiazides in this population. Dose titration of candesartan cilexetil is recommended in | |
& patients with renal impairment whose creatinine clearance is ³ 30 ml/min/1.73 m2 BSA before treatment with Atacand | |
& Plus (the recommended starting dose of candesartan cilexetil is 4 mg in patients with mild to moderate renal impairment). | |
& Atacand Plus should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73m2 BSA). | |
# Use in impaired hepatic function: | |
& Dose titration of candesartan cilexetil is recommended in patients with mild to moderate hepatic impairment before treatment | |
& with Atacand Plus (the recommended starting dose of candesartan cilexetil is 2 mg in these patients). | |
& Atacand Plus should not be used in patients with severe hepatic impairment &&/or cholestasis. | |
# Use in children: The safety && efficacy of Atacand Plus have not been established in children. | |
* Contra-indications: | |
– Hypersensitivity to the active substances or to any of the excipients or to sulfonamide derived drugs (hydrochlorothiazide | |
& is a sulfonamide derived drug). | |
– Pregnancy and lactation. | |
– Severe renal impairment (creatinine clearance <30 ml/min/1.73 m2 BSA). | |
– Severe hepatic impairment and/or cholestasis. | |
– Refractory hypokalaemia and hypercalcaemia. | |
– Gout. | |
* Special warnings and special precautions for use: | |
# Renal impairment/Kidney transplantation: | |
& Loop diuretics are preferred to thiazides in this population. When Atacand Plus is used in patients with impaired renal function, | |
& a periodic monitoring of potassium, creatinine and uric acid levels is recommended. | |
& There is no experience regarding the administration of Atacand Plus in patients with a recent kidney transplantation. | |
# Renal artery stenosis: | |
& Other drugs that affect the renin-angiotensin-aldosterone system, i.e. angiotensin converting enzyme (ACE) inhibitors, |
Weight | 100 kg |
---|
Q & A
There are no questions yet